Lexology March 15, 2023
Sidley Austin LLP

In the first of a series on surviving the current financial and regulatory environment, Torrey Cope looks at how life sciences companies can reduce difficulties in getting new products approved by the U.S. Food and Drug Administration through effective written submissions.

Life sciences companies currently face numerous challenges when seeking approval for new drugs and biological products. This is partly because the science of new product development has generally become harder, with more companies pursuing therapies in areas that have long proved difficult to crack.

At the same time, the COVID-19 pandemic created lingering difficulties for both life sciences companies and the FDA. These include a reduction in the face-to-face interactions typically needed to reach alignment on thorny scientific and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
To Give Rare Disease Patients Hope, the FDA Must Re-Focus its Efforts
Opinion: Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it
FDA clears heart rhythm AI that turns smartphones into medical devices
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Accelerated Approval Pathway for Cancer Drugs: Does It Work?

Share This Article